Use of once-daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real-world study (PIONEER REAL Canada).
Akshay B JainSonja M ReichertHanan AmadidUffe C BraaeRyan M BradleyJames W KimVictoria SooJean-François YalePublished in: Diabetes, obesity & metabolism (2024)
In PIONEER REAL Canada, participants treated with oral semaglutide in routine clinical practice experienced clinically relevant reductions in HbA1c and BW and increased treatment satisfaction.